Sun Pharma develops and supplies specialty medicines, branded generics, generics and APIs across a wide therapeutic spectrum. Its products are manufactured at 40 sites and reach over 100 countries worldwide.

The FY25 revenue distribution shows India at 33% while International markets comprise 67% of the total and by business sector the figures are India 33%, US 31%, Emerging Markets 18%, RoW 14% and API and Others 4%.

The consolidated financial statements include 102 subsidiaries as listed in Note 38 of the Annual Report